WilmerHale Reps Nabriva Therapeutics in $80M Public Offering of Ordinary Shares

WilmerHale Reps Nabriva Therapeutics in $80M Public Offering of Ordinary Shares

Firm News

On September 22, 2017, Nabriva Therapeutics plc (NASDAQ:NBRV) closed on its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $8.50 per share, totaling approximately $80 million.

Brian Johnson led the WilmerHale team representing Nabriva in this transaction, which also included Scott Lunin and Alicia Lee.

Nabriva's announcement regarding the pricing of this offering can be found at www.nabriva.com.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.